Gilead Sciences Inc. (GILD)
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
GILD vs. ALNY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks is more attractive to value investors?
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Stacey Ma - Executive Vice President, Pharmaceutical Development and Manufacturing Andrew Dickinson - Chief Financial Officer Flavius Martin - Executive Vice President, Research Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be introducing Gilead today.
Gilead CEO on funding for new HIV prevention medicine
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join ‘Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and more.
